Hi-Bio Announces $95 Million Series B Financing To Advance Targeted Therapies For Immune-Mediated Diseases
Amount Raised
$95 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareBiotechnology ResearchInvestors
Description
Human Immunology Biosciences (HI-BioTM), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.
Quick answer
BioGen raised $95 Million in a Series B round, dated January 4, 2024. Investors: ARCH Venture Partners, Jeito Capital, Arkin Bio Capital, Viking Global Investors and Alpha Wave Global. BioGen is based in Cambridge, Massachusetts, United States.
- How much did BioGen raise?
- BioGen raised $95 Million in a Series B round on January 4, 2024.
- Who invested in BioGen?
- ARCH Venture Partners, Jeito Capital, Arkin Bio Capital, Viking Global Investors and Alpha Wave Global are named as investors in this round.
- What does BioGen do?
- BioGen is a biotechnology company specializing in the development of therapies for neurological diseases.
- Where is BioGen based and how big is it?
- BioGen is based in Cambridge, Massachusetts, United States. Fundz records about 7,553 employees.
- Who are the decision-makers at BioGen?
- Fundz holds 1 contact at BioGen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology Research and Biotechnology around the same time
Companies in the same sectors as BioGen that raised within 45 days of this round, from Fundz verified event records.
- Sudo Biosciences raised $147M (Series B) on February 13, 2024.
- Liquidia raised $100M (Funding Round) on January 4, 2024.
- Daré Bioscience, Inc. raised $12M on December 26, 2023.
- Daré Bioscience, Inc. raised $1.7M (Seed) on December 21, 2023.
- Sudo Biosciences raised $116M (Series B) on December 20, 2023.
- Sudo Biosciences raised $53M on December 15, 2023.
Who to call at BioGen, and when
A new round usually means BioGen is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day BioGen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioGen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioGen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioGen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansBioGen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.